# Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

> **NCT01032408** · PHASE3 · COMPLETED · sponsor: **Chiltern Pesquisa Clinica Ltda** · enrollment: 154 (actual)

## Conditions studied

- H1N1 Influenza Virus
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection

## Interventions

- **BIOLOGICAL:** Focetria®
- **BIOLOGICAL:** Begrivac®

## Key facts

- **NCT ID:** NCT01032408
- **Lead sponsor:** Chiltern Pesquisa Clinica Ltda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-09
- **Final completion:** 2012-07
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032408, "Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01032408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*